Stemline Therapeutics (NASDAQ:STML) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Friday, January 26th.
Several other equities analysts have also recently issued reports on the company. Zacks Investment Research upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, January 5th. ValuEngine raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. HC Wainwright set a $38.00 price objective on Stemline Therapeutics and gave the company a “buy” rating in a report on Thursday, December 14th. Finally, Cowen reissued a “buy” rating on shares of Stemline Therapeutics in a research note on Tuesday, October 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $33.75.
Shares of Stemline Therapeutics (NASDAQ STML) opened at $15.35 on Friday. Stemline Therapeutics has a 52-week low of $6.35 and a 52-week high of $17.40. The company has a market capitalization of $444.72, a PE ratio of -5.97 and a beta of -0.02.
In other Stemline Therapeutics news, insider David Gionco sold 4,250 shares of the business’s stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $13.43, for a total value of $57,077.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Kenneth Hoberman sold 11,943 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $14.18, for a total value of $169,351.74. The disclosure for this sale can be found here. Insiders have sold a total of 42,216 shares of company stock valued at $591,925 over the last 90 days. Insiders own 15.70% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the business. Royce & Associates LP acquired a new position in Stemline Therapeutics in the 4th quarter valued at $106,000. Voya Investment Management LLC acquired a new stake in shares of Stemline Therapeutics during the 2nd quarter worth $102,000. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Stemline Therapeutics during the 4th quarter worth $189,000. Nationwide Fund Advisors increased its holdings in shares of Stemline Therapeutics by 7.2% during the 2nd quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 855 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Stemline Therapeutics by 40.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,279 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 5,522 shares during the last quarter. Institutional investors own 42.85% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Stemline Therapeutics (NASDAQ:STML) Lifted to “Hold” at BidaskClub” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/13/stemline-therapeutics-stml-raised-to-hold-at-bidaskclub.html.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.